← Back to Search

Lung Protective Ventilation for Brain Injury (NEUROVENT Trial)

N/A

Waitlist Available

Led By Colin K Grissom, MD

Research Sponsored by Colin Grissom

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up day of admission to day of discharge, an average of 10 days

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing a computerized ventilator protocol in iCentra that is designed to improve outcomes for patients with acute brain injury by targeting a normal partial pressure of carbon dioxide while using the lowest ventilator volume required.

Who is the study for?

This trial is for adults (18+) with acute brain injury, either from non-traumatic causes like stroke or anoxic brain injury, or from traumatic events. They must be starting mechanical ventilation in the emergency department or ICU at an Intermountain Healthcare hospital.

What is being tested?

The study tests a computerized ventilator protocol aiming to maintain normal carbon dioxide levels in blood while using the lowest necessary ventilator volume. It's designed to prevent further lung damage and improve outcomes for patients with acute brain injuries.

What are the potential side effects?

While not explicitly listed, potential side effects may include discomfort due to lower ventilator volumes and possible complications if optimal carbon dioxide levels are not maintained.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ day of admission to day of discharge, an average of 10 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~day of admission to day of discharge, an average of 10 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and day of admission to day of discharge, an average of 10 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Secondary study objectives

Average number of protocol deviations for all subjects (protocol compliance)

Health Care Utilization

Hospital Discharge Disposition

+1 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Lung Protective VentilationExperimental Treatment1 Intervention

Subjects with acute brain injury (traumatic brain injury and non-traumatic brain injury) will receive neuro lung protective ventilation which targets a normal arterial partial pressure of carbon dioxide with the lowest tidal volume possible (6 to 8 ml/kg predicted body weight). Protocols for oxygenation and weaning from the ventilator will also be followed.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Lung Protective Ventilation

2018

N/A

~20

Do I qualify?Apply below to find out